
-
Caribou Biosciences NasdaqGS:CRBU Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Location: 2929 7th Street, Berkeley, CA, 94710, United States | Website: https://cariboubio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-74.36M
Cash
208.5M
Avg Qtr Burn
-34.43M
Short % of Float
11.31%
Insider Ownership
9.83%
Institutional Own.
53.40%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CB-010 Details Non-Hodgkin lymphoma, Cancer, Blood cancer | Phase 1 Data readout | |
CB-011 Details Blood cancer, Cancer, Multiple myeloma | Phase 1 Data readout | |
CB-012 Details Acute myeloid leukemia, Cancer | Phase 1 Update | |
CB-010 Details Lupus nephritis, Extrarenal lupus | Phase 1 Update |